ARTICLE | Emerging Company Profile
Bionyra: Pairing longer-lived antibodies with emerging I&I targets
Transatlantic biotech launched last month with $165M series A round to advance three in-licensed antibodies
July 28, 2026 11:42 PM UTC
Bionyra is building an inflammation pipeline around two ideas: extending antibody half-life to reduce dosing burden and pursuing emerging targets, alone or in combination with validated mechanisms, to improve efficacy.
Bionyra, which is based in Paris and Boston, has in-licensed three programs: BYN-002 and BYN-003 from China-based TrueLab Biopharmaceutical Co. Ltd. (帆礼生物), and BYN-001 from New Jersey biotech NovaRock Biotherapeutics Inc. As such, the start-up is among the 13 NewCos formed in 1H26, VC-backed biotechs launching in the West around assets from Asia...
BCIQ Company Profiles